Research Topics
| David I QuinnSummaryAffiliation: University of Southern California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Molecular markers of prostate cancer outcomeDavid I Quinn
Division of Oncology, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastalke Avenue, Suite 3453, Los Angeles, CA 90033, USA
Eur J Cancer 41:858-87. 2005..By integrating selected markers into prospective clinical trials, there is potential for us to provide specific targeted therapy tailored for an increasing number of patients...
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myelomaDavid I Quinn
University of Southern California, Los Angeles, California, USA
Clin Pharmacokinet 48:199-209. 2009..The variability of bortezomib pharmacokinetics with CYP enzyme polymorphism was also investigated...- One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancerKathleen Ell
School of Social Work, University of Southern California, 669 W 34th St, Los Angeles, CA 90089 0411, USA
Psychiatr Serv 62:162-70. 2011..This study assessed longer-term outcomes of low-income patients with cancer (predominantly female and Hispanic) after treatment in a collaborative model of depression care or in enhanced usual care... 
Randomized controlled trial of collaborative care management of depression among low-income patients with cancerKathleen Ell
School of Social Work and Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 0411, USA
J Clin Oncol 26:4488-96. 2008..To determine the effectiveness of the Alleviating Depression Among Patients With Cancer (ADAPt-C) collaborative care management for major depression or dysthymia...- Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumorsSyma Iqbal
Department of Medical Oncology, University of Southern California Norris Cancer Center, Los Angeles, CA 90033, USA
Am J Clin Oncol 34:27-31. 2011..The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors... - Blood cells and their use in active immunotherapy of prostate cancerShuang Yin Zhang
University of Southern California, Medicine, Los Angeles, CA, USA
Hum Vaccin Immunother 8:528-33. 2012..We review the components of the immune system which may be harnessed in the development of immunotherapy in the setting of the recent success with sipuleucel-T... - Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell linesCarmen Plasencia
Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, 90089, USA
Mol Cancer Ther 4:1105-13. 2005.... - EphB4 expression and biological significance in prostate cancerGuangbin Xia
Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, USA
Cancer Res 65:4623-32. 2005..These data show a role for EphB4 in prostate cancer and provide a rationale to study EphB4 for diagnostic, prognostic, and therapeutic applications... - Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancerGuangbin Xia
Department of Medicine, Keck School of Medicine of the University of Southern California, California, USA
J Urol 175:1245-52. 2006..Therefore, we studied the expression of VEGF and VEGFR2 in bladder cancer, and the relationship to disease characteristics... - Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trialEric Cheung
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA
Clin Genitourin Cancer 7:43-50. 2009..Fenretinide is a synthetic retinoid that is cytotoxic to a variety of cancers. We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer... - Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
Clin Cancer Res 16:3028-34. 2010..Interleukin-6 (IL-6) facilitates cancer cell survival via pleotrophic effects. We conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer... - Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancerHossein Jadvar
Division of Nuclear Medicine, Department of Radiology, Kenneth J Norris Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Clin Nucl Med 37:637-43. 2012..This study aimed to perform a prospective evaluation of 18F-NaF and 18F-FDG PET/CT in the detection of occult metastatic disease in men with prostate cancer and biochemical relapse... - Vaccine therapy with sipuleucel-T (Provenge) for prostate cancerEddie Thara
Division of Cancer Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States
Maturitas 69:296-303. 2011.... - Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacyAlexandra M Levine
Department of Medicine, University of Southern California USC, Keck School of Medicine, Los Angeles, CA 90033, USA
J Clin Oncol 24:1712-9. 2006..This study established the safety, biologic effects, and pharmacokinetics of VEGF-AS in 51 patients with advanced malignancies... - Natural history of surgically treated bladder carcinoma with extravesical tumor extensionMarcus L Quek
Department of Urology, Kenneth Norris Jr Comprehensive Cancer Center, University of Southern California Keck School of Medicine, MS 74, 1441 Eastlake Avenue, Suite 7476, Los Angeles, CA, USA
Cancer 98:955-61. 2003..The authors evaluated the outcomes of patients with pT3a and pT3b disease after radical cystectomy... - Microscopic and gross extravesical extension in pathological staging of bladder cancerMarcus L Quek
Department of Urology, Kenneth Norris, Jr Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, 90089, USA
J Urol 171:640-5. 2004..We evaluated clinical outcomes in patients with pathological microscopic (pT3a) and gross (pT3b) extravesical tumor extension with transitional cell carcinoma (TCC) of the bladder following radical cystectomy... - Factors influencing post-recurrence survival in bladder cancer following radical cystectomyAnirban P Mitra
Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
BJU Int 109:846-54. 2012..To identify prognostic indicators that influence post-recurrence survival following radical cystectomy for bladder cancer... - Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experienceTanya B Dorff
USC Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA
World J Urol 27:39-44. 2009.... - The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomyAna M Aparicio
Division of Medical Oncology and Kenneth J. Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
Urol Clin North Am 32:217-30, vii. 2005..The chemotherapy of urological malignancies, including bladder cancer, has recently been reviewed in detail; this article does not contain an extensive review of the drugs used... - Molecular prognostic factors in bladder cancerMaurizio Buscarini
Department of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern Californua Keck School of Medicine, Los Angeles, California 90089, USA
BJU Int 95:739-42. 2005 - Small cell bladder cancer: biology and managementElie Fahed
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
Semin Oncol 39:615-8. 2012..Better understanding of the molecular alterations driving SCBC may facilitate the development of new therapeutic strategies and improved outcomes... - Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C studyKathleen Ell
School of Social Work, University of Southern California, Los Angeles, CA 90089 0411, USA
Gen Hosp Psychiatry 29:223-31. 2007..The primary goal is to test the effectiveness of socioculturally tailored collaborative care intervention in improving depression and quality of life outcomes among low-income ethnic minority patients with major depression and cancer... - Targeted therapy in renal cancerTanya B Dorff
Assistant Professors of Medicine, Kenneth J Norris Comprehensive Cancer Center, Section of Genitourinary Medical Oncology, Division of Cancer Medicine and Blood Diseases, University of Southern California, Los Angeles CA, USA
Ther Adv Med Oncol 1:183-205. 2009..This review focuses on the background, clinical development and practical use of these new drugs in RCC... - Pain management, supportive and palliative care in patients with renal cell carcinomaJeffrey S Turner
Kenneth J. Norris Jr Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
BJU Int 99:1305-12. 2007 - Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serumJohn B Welsh
Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
Proc Natl Acad Sci U S A 100:3410-5. 2003.... - SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibitionPrimo N Lara
University of California Davis Cancer Center, Sacramento, California 95817, USA
Clin Cancer Res 9:4772-81. 2003..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans... - A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancerIlias Cagiannos
Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Urol 170:1798-803. 2003..CONCLUSIONS: Using clinical information, we produced 2 calibrated and validated nomograms, which accurately predict pathologically negative lymph nodes in men with localized prostate cancer who are candidates for radical prostatectomy... - International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomyMarkus Graefen
Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 20:3206-12. 2002..Our results demonstrate that accurate predictions may be expected across different patient populations... - Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomySusan M Henshall
Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, NSW 2010, Australia
J Natl Cancer Inst 98:1420-4. 2006.... - Angiogenesis-targeted therapies in prostate cancerPrimo N Lara
University of California Davis Cancer Center, 4501 X St, Suite 3016, Sacramento, CA 95817, USA
Clin Prostate Cancer 3:165-73. 2004..This review summarizes the molecular mechanisms implicating angiogenesis in the development and progression of advanced-stage prostate cancer, as well as the drug development efforts that are targeting this process... - A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastasesPrimo N Lara
University of California Davis Cancer Center and the University of California Davis School of Medicine, Sacramento, California 95817, USA
Clin Cancer Res 12:1556-63. 2006..Serial serum and urine specimens were collected to assess for markers of bone metabolism... - Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasionDavid I Quinn
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
Cancer 97:1884-93. 2003.... - Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patientsMark E Newell
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
Cancer 100:2627-36. 2004..This combination of therapies may provide a standard of care as the basis for further trials of chemotherapy, novel adjunctive treatment, and quality of life assessment... - Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancerMarkus Graefen
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:951-6. 2002..CONCLUSION: The postoperative Baylor nomogram was accurate when applied at international treatment institutions. Our results suggest that accurate predictions may be expected when using this nomogram across different patient populations... - Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapseSusan M Henshall
Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia
Cancer Res 63:4196-203. 2003.... - Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancerSusan M Henshall
Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, 384 Victoria Street, Darlinghurst NSW 2010, Australia
Oncogene 22:6005-12. 2003..These findings are consistent with a role for ZnT4 in vesicular transport of zinc to the cell membrane and potentially in efflux of zinc in the prostate... - Is year of radical prostatectomy a predictor of outcome in prostate cancer?Ilias Cagiannos
Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Urol 171:692-6. 2004..We examined whether the year in which radical prostatectomy (RP) was performed is a predictor of treatment outcome after controlling for standard prognostic factors... - Postchemotherapy residual masses in advanced seminoma: current management and outcomesMarcus L Quek
Department of Urology, Loyola University Stritch School of Medicine, IL 60153, USA
Expert Rev Anticancer Ther 5:869-74. 2005..The incorporation of noninvasive imaging modalities, such as positron emission tomography, into the management algorithm may better delineate the presence of viable residual tumor and thus allow better risk stratification... - The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trialKaren G Chee
University of California Davis Cancer Center, Sacramento, CA 95817, USA
Clin Genitourin Cancer 5:433-7. 2007..Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation. We conducted a phase II trial of perifosine in patients with biochemically recurrent, hormone-sensitive prostate cancer... - Cytokine therapy: a standard of care for metastatic renal cell carcinoma?Thomas E Hutson
Genitourinary Oncology Program, Texas Oncology, PA, Baylor Charles A Sammons Cancer Center, Dallas, TX 75254, USA
Clin Genitourin Cancer 4:181-6. 2005..Until results from ongoing trials clearly demonstrate superiority of newer agents over IFN-alpha or IL-2, these agents should remain a standard of care for the treatment of RCC... - Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trialPrimo N Lara
University of California, Davis Cancer Center, Sacramento, California 95817, USA
J Thorac Oncol 1:126-34. 2006..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors... - Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignanciesTomasz M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA
Cancer 106:2624-9. 2006..To the authors' knowledge, no satisfactory therapy is available for patients with refractory germ cell neoplasms. The activity and safety of arsenic trioxide in refractory germ cell tumors was assessed... - A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinomaWalter M Stadler
Department of Medicine, Section of Hematology Oncology and Urology, University of Chicago, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637, USA
Cancer Chemother Pharmacol 61:689-94. 2008..GTI-2040 is a 20-mer phosphorothioate oligonucleotide complimentary to the R2 component of ribonucleotide reductase that has activity in renal cancer models...